Atrial Fibrillation
Conditions
Brief summary
This prospective observational study is to assess the predictive factors of poor control of international normalized ratio (INR) to determine the treatment strategies received by patients with a poor control of INR in real-life clinical practice and to explore the effectiveness and safety of these strategies in patients with non-valvular atrial fibrillation who start vitamin K antagonist (VKA) treatment
Interventions
The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥ 18 years. * Patients with a diagnosis of nonvalvular atrial fibrillation according to the criteria of the Spanish Agency of Medicines and Medical Devices (AEMPS) (2013) who are treated in cardiology practices. * Patients about to start treatment with a vitamin K antagonist or who are in the first two months of treatment. * Patients for whom access to at least 80% of INR tests performed during treatment with vitamin K antagonists is expected to be available. * Patients with the mental and physical capacity to complete the study questionnaires and give their informed consent to participate in the study.
Exclusion criteria
* Patients with mitral stenosis or another significant valve disease for which specific treatment is scheduled or has already been performed (prosthesis or valvuloplasty). * Patients hospitalised at the time of inclusion in the study. * Patients with a life expectancy of less than 13 months. * Patients who are participating in a clinical trial. * Patients receiving double antiplatelet therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| International Normalized Ratio (INR) Time in Therapeutic Range (TTR) | Up to 24 months | Percentage of time within an INR range of 2-3 estimated using the Rosendaal method |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Baseline thromboembolic risk based on the CHA2DS2-VASc scale | Baseline | CHA2DS2-VASc:Cardiac failure, Hypertension, Age ≥75, Diabetes, Stroke -Vascular disease, Age and sex category |
| Baseline haemorrhagic risk based on the HAS-BLED scale | Baseline | HAS-BLED: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly , Drugs/alcohol |
| Changes in INR time in therapeutic range | Up to 24 months | INR time in therapeutic range: percentage of time within an INR range of 2-3 estimated using the Rosendaal method |
| Patient preferences with regard to anticoagulant treatment based on patients' questionnaires | Up to 12 months | — |
| Satisfaction with the anticoagulant treatment based on the Anti-Clot Treatment Scale (ACTS) | Up to 12 months | — |
| Baseline thromboembolic risk based on the CHADS2 scale | Baseline | CHADS2: Cardiac failure, Hypertension, Age, Diabetes, Stroke |
| Number and type of visits by patients to health professionals related to their anticoagulant treatment | Up to 12 months | — |
| Number of patients using anticoagulant treatment strategies | Up to 24 months | Strategies: patients continuing vitamin K antagonists, patients with changes/adjustments to the dose of vitamin K antagonists and patients whose treatment is changed to direct action oral anticoagulants |
| Number of patients treated according to clinical practice guidelines based on the Spanish Agency of Medicines and Medical Devices (AEMPS) therapeutic positioning report | Up to 24 months | — |
| Number of thromboembolic events in patients with inadequate anticoagulation management | Up to 24 months | — |
| Number of haemorrhagic events in patients with inadequate anticoagulation management | Up to 24 months | — |
| Adherence to the anticoagulant treatment: Morisky-Green test | Up to 12 months | — |
Countries
Spain
Outcome results
None listed